| Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles. | |
| | |
MedLine Citation:
|
PMID: 9352741 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We have treated 9 patients with sickle cell anemia (SS) with hydroxyurea (HU). All 9 patients carried 4 alpha-globin genes and the beta s-globin haplotypes 19/19 (Benin/Benin), except for 1 who had haplotype 19 together with type 3 (Benin/Senegal). Six patients received HU for 10 months and were again treated with the drug for 5 months after an interval of 1 year. One patient was given HU for 22 consecutive months. A record was kept of hematological and biochemical data, Hb F and G gamma levels, as well as possible clinical complications. Our data show that HU generally improves the hematological and biochemical values and the level of Hb F, and reduces painful crises in some patients. However, although the clinical symptoms improved in some patients during HU therapy, the older patients did not observe any changes in their general condition; the same is the case for the patient with haplotype 19/3. One patient also experienced life-threatening liver sequestration during treatment. We conclude that the selection of patients who may benefit from HU therapy needs further evaluation. |
| | |
Authors:
|
A W Saleh; H J Velvis; L H Gu; H F Hillen; T H Huisman |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Acta haematologica Volume: 98 ISSN: 0001-5792 ISO Abbreviation: Acta Haematol. Publication Date: 1997 |
Date Detail:
|
Created Date: 1997-12-05 Completed Date: 1997-12-05 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0141053 Medline TA: Acta Haematol Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 125-9 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, St. Elisabeth Hospital, Curaçao, The Netherlands Antilles. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anemia, Sickle Cell / drug therapy* Antisickling Agents / administration & dosage, adverse effects, therapeutic use* Drug Administration Schedule Female Fetal Hemoglobin / analysis Humans Hydroxyurea / administration & dosage, adverse effects, therapeutic use* Male Middle Aged Netherlands |
| Grant Support | |
ID/Acronym/Agency:
|
HLB-05168/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antisickling Agents; 127-07-1/Hydroxyurea; 9034-63-3/Fetal Hemoglobin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Serum levels of G-CSF, IL-3, IL-6 and GM-CSF after a single intraperitoneal dose of rhG-CSF in letha...
Next Document: Prognostic factors in elderly patients with non-Hodgkin's lymphoma treated with cyclophosphamide, vi...